On August 6, 2007, the United States Food and Drug Administration (FDA) approved maraviroc (Selzentry), the first drug to be approved in the CCR5 coreceptor antagonist class of anti-HIV medications.
Maraviroc has been approved for use in conjunction with other antiretrovirals in treatment-experienced adults who have exclusively CCR5-tropic HIV virus, evidence of viral replication, and resistance to multiple antiretroviral medications. read more
No comments:
Post a Comment